EUVIMEDEUVIMED entdecken
Open Access

SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection

Ahsan S Farooqi, Alison K Yoder, Heather Y Lin, Dario Pasalic, Jeremy Erasmus, Sonia Betancourt, Cort Wernz, Devarati Mitra, Maria A Zarzour, Neeta Somaiah, Anthony Conley, Ravin Ratan und 9 weitere

International Journal of Radiation Oncology*Biology*Physics · 2024-03 · 118 (4) · 971-978

DOI: 10.1016/j.ijrobp.2023.10.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-03. Verfasst von Ahsan S Farooqi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: afarooqi@mdanderson.org. Hauptthemen laut MEDLINE: Lung Neoplasms, Soft Tissue Neoplasms, Sarcoma, Radiosurgery. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The lungs are the most common site of metastasis for patients with soft tissue sarcoma. SABR is commonly employed to treat lung metastases among select patients with sarcoma with limited disease burden. We sought to evaluate outcomes and patterns of failure among patients with sarcoma treated with SABR for their lung metastases. METHODS AND MATERIALS: We performed a retrospective review of patients treated at a tertiary cancer center between 2006 and 2020. Patient disease status at the time of SABR was categorized as either oligorecurrent or oligoprogressive. The Kaplan-Meier method was used to estimate disease outcomes. Uni- and multivariable analyses were conducted using the Cox proportional hazards model. RESULTS: We identified 70 patients with soft tissue sarcoma treated with SABR to 98 metastatic lung lesions. Local recurrence-free survival after SABR treatment was 83% at 2 years. On univariable analysis, receipt of comprehensive SABR to all sites of pulmonary metastatic disease at the time of treatment was associated with improved progression-free survival (PFS; hazard ratio [HR], 0.51 [0.29-0.88]; P = .02). On multivariable analysis, only having systemic disease controlled at the time of SABR predicted improved PFS (median PFS, 14 vs 4 months; HR, 0.37 [0.20-0.69]; P = .002) and overall survival (median overall survival, 51 vs 14 months; HR, 0.17 [0.08-0.35]; P < .0001). CONCLUSIONS: SABR provides durable long-term local control for sarcoma lung metastases. The most important predictor for improved outcomes was systemic disease control. Careful consideration of these factors should help guide decisions in a multidisciplinary setting to appropriately select the optimal candidates for SABR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSoft Tissue NeoplasmsSarcomaRadiosurgeryHumansPatient SelectionRetrospective StudiesTreatment Outcome

Autor:innen und Institutionen

  • Departments of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: afarooqi@mdanderson.org.
  • Departments of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Farooqi, A. S., Yoder, A. K., Lin, H. Y., Pasalic, D., Erasmus, J., Betancourt, S., Wernz, C., Mitra, D., Zarzour, M. A., Somaiah, N., Conley, A., Ratan, R., Livingston, A., Araujo, D. M., Roland, C., Scally, C., Keung, E., Gandhi, S. N., Ashleigh Guadagnolo, B., …, & Bishop, A. J. (2024). SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. International Journal of Radiation Oncology*Biology*Physics, 118(4), 971-978. https://doi.org/10.1016/j.ijrobp.2023.10.017

Vancouver

Farooqi AS, Yoder AK, Lin HY, Pasalic D, Erasmus J, Betancourt S, et al. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. International Journal of Radiation Oncology*Biology*Physics. 2024;118(4):971-978. doi:10.1016/j.ijrobp.2023.10.017

BibTeX
@article{Farooqi2024,
  author = {Farooqi, Ahsan S and Yoder, Alison K and Lin, Heather Y and Pasalic, Dario and Erasmus, Jeremy and Betancourt, Sonia and Wernz, Cort and Mitra, Devarati and Zarzour, Maria A and Somaiah, Neeta and Conley, Anthony and Ratan, Ravin and Livingston, Andrew and Araujo, Dejka M and Roland, Christina and Scally, Christopher and Keung, Emily and Gandhi, Saumil N and Ashleigh Guadagnolo, B and Nguyen, Quynh-Nhu and Bishop, Andrew J},
  title = {SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  volume = {118},
  number = {4},
  pages = {971--978},
  doi = {10.1016/j.ijrobp.2023.10.017}
}
Kostenlos starten →